Gilead Appoints John C. Martin as Chairman of Board of Directors; Names John F. Milligan President

FOSTER CITY, Calif.--(BUSINESS WIRE)--May 7, 2008--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that John C. Martin, PhD has been appointed Chairman of the Board of Directors, and John F. Milligan, PhD has been appointed President.

Dr. Martin will continue to serve as Gilead's Chief Executive Officer. He is assuming the additional role of Chairman of the Board from James M. Denny, who will remain a member of Gilead's Board of Directors, serving as lead director. Mr. Denny joined Gilead's Board in 1996 and was appointed Chairman in 2001. Dr. Milligan will continue to serve as Gilead's Chief Operating Officer, in addition to his new role of President.

"I have had the honor of serving as the Chairman of Gilead's Board of Directors for the past seven years and the opportunity to observe the leadership and vision that John Martin and John Milligan both bring to Gilead," commented Mr. Denny. "I look forward to working with them in their new roles as they continue to guide Gilead's efforts to bring novel therapies to patients affected by life-threatening diseases around the world."

Dr. Martin joined Gilead in 1990 and was appointed President and Chief Executive Officer in 1996. Prior to joining Gilead, Dr. Martin held several leadership positions in the antiviral chemistry division at Bristol-Myers Squibb and served for six years with Syntex Corporation, from 1978 until 1984. He is a member of the Presidential Advisory Council on HIV/AIDS, the Board of Directors of Gen-Probe Incorporated and the Board of Directors of the California Healthcare Institute.

Dr. Martin holds a PhD in organic chemistry from the University of Chicago and an MBA in marketing from Golden Gate University.

Dr. Milligan also joined Gilead in 1990, beginning his career at the company as a Research Scientist. He has held leadership roles in Project Management and Corporate Development. In 2002, Dr. Milligan was appointed Chief Financial Officer (CFO). He was named Chief Operating Officer in 2007.

He holds a PhD in biochemistry from the University of Illinois and was an American Cancer Society Postdoctoral fellow at the University of California at San Francisco. Dr. Milligan was named "Bay Area CFO of the Year" in 2006 for companies with revenues greater than $500 million, and he was named the top biotechnology industry CFO in the United States by Institutional Investor magazine in 2006, 2007 and 2008.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors, including risks related to Gilead's ability to develop and deliver novel therapies to patients. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in the Gilead Annual Report on Form 10-K for the year ended December 31, 2007 as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead and Gilead assumes no obligation to update any such forward-looking statements.

For more information on Gilead Sciences, please visit the company's website at www.gilead.com or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

CONTACT: Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715 (Investors)
Amy Flood, 650-522-5643 (Media)
SOURCE: Gilead Sciences, Inc.